Amarin Corp Plc (AMRN)

[Pharmacydude]

Gusman
Neither the pharmacy nor the insurance company is violating the patents if they offer the Pt Vascepa-R-IT at $300 and gV for $10. It is the Pt (in the eyes of the law) who is violating the patent and choosing gV because it costs them less. HealthNet’s entire defence is that it is not considered inducement if all you do is make product A less expensive than product B. It’s the person who buys the product who is responsible.
The only solution is exclusivity contracts like MK is negotiating now.